Tonix Pharmaceuticals shares are trading higher after the company secured a $34 million DOD research collaboration contract with X-Chem.
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals shares rose after securing a $34 million research collaboration contract with the Department of Defense and X-Chem.
October 08, 2024 | 1:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals' stock is trading higher following the announcement of a $34 million research collaboration contract with the Department of Defense and X-Chem.
The $34 million contract with the Department of Defense and X-Chem is a significant development for Tonix Pharmaceuticals, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100